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Abstract
The EVI1 (ecotropic viral integration site 1) gene at 3q26 codes for a transcriptional regulator with an essential role in
haematopoiesis. Overexpression of EVI1 in acute myeloid leukaemia (AML) is frequently associated with 3q26
rearrangements and confers extremely poor prognosis. EVI1 mediates transcriptional regulation, signalling, and epigenetic
modifications by interacting with DNA, proteins and protein complexes. To explore to what extent protein phosphorylation
impacts on EVI1 functions, we analysed endogenous EVI1 protein from a high EVI1 expressing Fanconi anaemia (FA) derived
AML cell line. Mass spectrometric analysis of immunoprecipitated EVI1 revealed phosphorylation at serine 196 (S196) in the
sixth zinc finger of the N-terminal zinc finger domain. Mutated EVI1 with an aspartate substitution at serine 196 (S196D),
which mimics serine phosphorylation of this site, exhibited reduced DNA-binding and transcriptional repression from a
gene promotor selectively targeted by the N-terminal zinc finger domain. Forced expression of the S196D mutant
significantly reduced EVI1 mediated transformation of Rat1 fibroblasts. While EVI1-mediated serial replating of murine
haematopoietic progenitors was maintained by EVI1-S196D, this was associated with significantly higher Evi1-trancript
levels compared with WT-EVI1 or EVI1-S196A, mimicking S196 non-phosphorylated EVI1. These data suggest that EVI1
function is modulated by phosphorylation of the first zinc finger domain.
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Introduction
The Ecotropic viral integration site-1 gene (EVI1), at the MECOM
(MDS-EVI1 complex) locus at 3q26.2 encodes a nuclear protein
with an essential role in haematopoiesis [1]. Overexpression of
EVI1 in acute myeloid leukaemia (AML) is commonly a result of
chromosomal rearrangements involving the 3q26.2 region and is
associated with an extremely poor clinical outcome [2,3]. EVI1
overexpression is in particular linked to leukemic transformation in
individuals with Fanconi Anaemia (FA), which is an inherited
chromosomal fragility disorder with predisposition to AML [4,5].
EVI1 functions as a transcriptional regulator with two zinc finger
domains that recognize specific genomic DNA target sequences
[6,7] and mediates interaction of DNA with chromatin modifying
proteins and protein complexes to regulate gene expression
[8,9,10]. EVI1 regulated genes have been reported to include
Pbx1 and Fos [11,12]. The oncogenic potential of overexpressed
EVI1 is reflected by the transformation of Rat1 fibroblasts to
anchorage independent growth [13], as well as EVI1 induced
immortalization of primary bone marrow cells, and induction of
myeloid dysplastic syndrome in mice [13,14,15]. EVI1-mediated
transformation in vitro and in vivo, however, has been shown to be
abrogated when interactions between EVI1 and its co-regulatory
protein complexes, or its target DNA sequences are disrupted
[16,17]. Protein phosphorylation has been shown to be an
important modulator of transcriptional regulators in development,
haematopoiesis and differentiation [18,19,20]. Phosphorylation of
EVI1 was first identified by metabolic labelling studies more than
20 years ago [21], and more recently in large scale proteomic
studies [22,23,24]. To test the hypothesis that EVI1 phosphory-
lation plays a role in modulating EVI1 protein function, we
analysed endogenously expressed EVI1 from the FA-derived AML
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cell line SB1690CB by mass spectrometry and report here on the
functional analysis of EVI1 phosphorylation on serine 196 (S196).
Results
EVI1 is phosphorylated on Serine 196
We detected high EVI1 protein expression in the FA-derived
AML cell line SB1690CB, in which FA-associated 3q gains result
in high EVI1 transcript levels [5] (Figure 1A). This enabled
immunoprecipitation of sufficient endogenous EVI1 protein to
perform mass spectrometric analysis (Figure 1B). A multiple
reaction monitoring-initiated detection and sequencing (MIDAS)
scan for putative phosphopeptides detected a signal associated with
potential phosphorylation of the peptide SYTQFSNLCR. Phos-
phorylation at serine 196 (S196) of EVI1 was confirmed by
analysis of the MRM-triggered MS/MS spectrum from the
putative phosphopeptide (Figure 1C). S196 is part of the
evolutionarily conserved sixth zinc-finger motif within the N-
terminal zinc-finger domain of EVI1 (Figure 1D), which
specifically binds to the DNA sequence GA(T/C)AAGA(T/
C)AAGATAA [6]. In addition, we confirmed previously described
carboxy-terminal phosphorylation (S858 and S860) of EVI1 (data
not shown) [22,23].
Impact of S196 phosphorylation on EVI1 protein
structure
In order to determine the structural context of the phosphor-
ylated serine 196, a comparative model of the sixth EVI1 zinc
finger domain was generated using standard techniques with a
model of the human C2H2 type zinc finger of protein 484 (pdb
code 2EMH) as a template.
Serine 196 is on the surface of the zinc finger domain, which
allows it to accommodate the phosphate group (Figure 2A and
B). The impact of alanine and aspartate substitution at S196, used
for functional analysis of S196 phosphorylation, was also modelled
(Figure 2C and D). Given the solvent-exposed nature of this site,
both aspartate and alanine can also be accommodated with no van
der Waals overlaps. This suggests that the structural integrity of
the proximal EVI1 zinc finger domain is maintained in the S196
phosphorylated, and alanine or aspartate substituted protein.
Phosphorylation of S196 modulates DNA binding and
transcriptional repression by EVI1
To investigate whether modulation of EVI1 S196 modifies the
interaction with its target DNA sequences, we generated GST-
fusion proteins with GST fused to the first zinc-finger domain of
murine EVI1 [6], in which S196 was substituted with either
aspartate (S196D) to mimic constitutively phosphorylated serine,
or alanine (S196A), which mimics non-phosphorylated serine. We
confirmed the strong interaction between the wtEVI1-GST fusion
protein and the double stranded oligonucleotide containing the
target DNA sequence GA(T/C)AAGA(T/C)AAGATAA recog-
nized by the first zinc-finger domain of EVI1 by EMSA (Figure
3A) [6]. The S196A-substituted mutant EVI1-fusion protein
mimicking non-phosphorylated EVI1 had equivalent binding to
the target sequence as wtEVI1. However, the phosphomimetic
EVI1-fusion protein showed decreased DNA binding (Figure3A),
suggesting that phosphorylation status of S196 modulates DNA
binding of EVI1. We next assessed the impact of full length EVI1-
S196 mutants on transcriptional repression using luciferase
reporter constructs with PLZF and Fos promoters. In vitro, PLZF
is regulated by the proximal Evi1 zinc finger domain [25], while
the Fos promoter is regulated by the distal zinc-finger domain of
EVI1 [11]. Wt-EVI1 repressed transcription from both reporter
constructs (Figure 3 B and C). The Evi1-S196A mutant
mimicking non-phosphorylated Evi1 repressed transcription from
both reporter gene constructs as efficiently as wt-EVI1. In
contrast, the phosphomimetic Evi1-S196D mutant repressed
transcription from the Fos promoter, but repression from the
PLZF promotor was significantly abrogated, implying that S196
phosphorylation impacts selectively on transcriptional regulation
by the first zinc finger domain of EVI1 (Figure 3 B and C).
Western blot analysis confirmed similar protein levels of both
mutant and wt-EVI1 in the above described reporter assays
(Figure 3D).
Phosphorylation of S196 partially abrogates transforming
ability of Evi1
Transduction with EVI1 transforms Rat1 fibroblasts and
enables anchorage independent growth in soft agar [13,26].
Rat1 fibroblasts transduced with and stably expressing S196A
mutant EVI1 mimicking non-phosphorylated Evi1 had similar
colony forming capacity in soft agar as Rat1 fibroblasts transduced
with wt-Evi1. However, Rat1 fibroblasts stably expressing the
phosphomimetic EVI1 S196D mutation generated fewer (p,0.05,
t-test) and smaller colonies compared to wt-EVI1(Figure 4A+B),
despite similar Evi1 protein levels in all transduced Rat1 cells
populations (Figure 4C). This implies that the ability of EVI1 to
transform Rat1 fibroblasts is tightly regulated by the sixth zinc
finger motif of the N-terminal zinc finger domain and is also
modulated by S196 phosphorylation.
Phosphorylation of S196 modulates EVI1 mediated
replating capacity in murine haematopoietic progenitor
cells
To investigate EVI1 S196 phosphorylation in the context of
haematopoiesis, wt-EVI1 and phosphorylation site EVI1-mutants
were expressed in c-kit+ murine primary bone marrow progenitors
(Figure 5A). In serial replating assays progenitor cells transduced
with control vector only formed colonies for two rounds of
replating only, whereas cells with forced expression of exogenous
wt-EVI1 replated beyond four rounds as previously described [13]
(Figure 5B). The forced expression of either the EVI1-S196A or
EVI1-S196D mutants enhanced replating capacity to the same
extent as wt-EVI1 (Figure 5B). Morphological analysis of May-
Gru¨nwald-Giemsa stained cells at the end of the third round of
replating showed persistence of immature cell types in the wt-
EVI1, EVI1-S196A and EVI1-S196D transduced populations,
whereas vector control cells had almost completely differentiated
(Figures 5C and D). The comparable replating efficiency of
EVI1-S196D compared with wt-EVI1 and EVI1-S196A demon-
strates that the phospho-mutant retains sufficient function to
confer serial replating, despite the impaired function that was
demonstrated in the Rat1 fibroblasts assay. Since EVI1-mediated
serial replating of hematopoietic progenitors appears highly
dependent on EVI1-transcript levels, and is most effective with
intermediate levels of EVI1 expression [13], we hypothesized that
for replating of EVI1-S196D transduced progenitors higher EVI1-
S196D expression levels might compensate for the impaired
function that we demonstrate using in vitro and Rat1 fibroblast
assays. Cells harvested from colonies transduced with EVI1-
S196D showed significantly higher Evi1-expression after the first
round of plating compared with either wt-EVI1 or S196A
(p,0.01) (Figure 5E) by qRT-PCR analysis of Evi1 transcript
levels. Sequence analysis of Evi1 transcripts in the S196A and
S196D transduced cells showed that the Evi1 transcripts were
EVI1 S196 Phosphorylation
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expressed exclusively from the vector and not from the endoge-
nous Mecom locus (Figure 5F)
Discussion
Overexpression of EVI1 is one of the most adverse prognostic
markers in AML [2,3]. Insight into EVI1 function might therefore
have therapeutic implications for EVI1 overexpressing AML. We
hypothesised that the multiple functions of EVI1 might be partially
modulated by protein phosphorylation. Therefore, we analysed
endogenous EVI1 from an FA-derived AML cell line, which
expresses high EVI1 transcript and protein levels as a result of FA-
characteristic 3q gains [4,27,28]. This confirmed previously
reported EVI1 phosphorylation sites (S858 and S860, data not
shown), and detected a novel phosphorylation site at S196 within
the sixth zinc finger of the first zinc finger domain of EVI1. Using
the kinase substrate prediction software NetPhosK (http://www.
cbs.dtu.dk/services/NetPhosK/) and NetworKin (http://
networkin.info) several kinases were identified, which may be
active on the EVI1 S196 site. These included: PKC, GSK3, CaM-
II, CDC2, RSK, CKI, DNAPK, p38MAPK, PKA, PKG, ATM,
CKII or NEK. As this phosphorylation site was detected in
association with a defect in the FA-DNA damage response
pathway, further investigations will focus on DNAPK, ATM and
p38MAPK for this event, as these kinases in particular have been
implicated in FA and the DNA damage response [29,30,31].
An in silico analysis of the structural impact of EVI1 S196
phosphorylation does not predict structural changes of this
phosphorylation event on EVI1 structure. However, by functional
analysis of the phosphomimetic mutant we demonstrated de-
Figure 1. EVI1 is phosphorylated on Serine 196 in SB1690CB cells. (A) Western blot detection of EVI1 from whole cell lysate of leukemia cell
lines SB1690CB, MUTZ-3 and K562. A vertical line has been inserted to indicate a repositioned gel lane. (B) Silver staining of immunoprecipitated EVI1
protein (arrow) from large scale SB1690CB cultures. Negative control lane showing immunoprecipitation with an irrelevant IgG antibody. (C)
Extracted ion chromatograph showing signal intensity at time for the MRM transition 649.8.600.8 designed to selectively detect the EVI1 peptide
SYTQFSNLCR with a single serine or threonine phosphorylation. The threshold for triggering fragmentation and sequencing of the peptide was 100
counts per second (cps) and is indicated with a dashed line. A peak exceeding this threshold was eluted at 30.49 min and triggered fragmentation of
the peptide (arrow). Lower panel: product ion spectrum generated by peptide fragmentation. Detected y- or b-type fragment ions are indicated.
Sequence of the EVI1 phosphopeptide with the b-ion and y-ion series and position of the phosphorylated serine residue at the N-terminus of the
peptide is shown. (D) Illustration showing the location of phosphorylated peptide within the EVI1 protein, with hexagons for zinc finger (ZF) motifs
and acidic region, A-circle, at the carboxy terminal region (modified from [48]). Underlined is the serine residue at site of phosphorylation. Alignment
was carried out using the t-coffee algorithm at www.t-coffee.org [49]. Shown is alignment to human EVI1 amino acids H182 to C219 with the
phosphorylated peptide boxed in red.
doi:10.1371/journal.pone.0066510.g001
Figure 2. Structural context of phosphorylation and substitutions at EVI1 S196. Main chain is shown in white and side chains in blue.
Oxygen atoms on residue 196 are indicated by red spheres. (A) The zinc finger domain with unmodified serine, (B) phosphorylated serine, (C)
aspartate substitution and (D) alanine substitution. All residues can adopt a similar conformation and extend into the solvent.
doi:10.1371/journal.pone.0066510.g002
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creased DNA binding and selectively abolished transcriptional
repression from a promotor targeted by the first EVI1 zinc finger,
as the mutant Evi1-S196D had no effect on transcriptional
repression of the Fos promotor, which is regulated by the second
zinc finger domain [11]. In the Rat1 fibroblast assay a mutation
mimicking phosphorylated Evi1-S196 nearly entirely abrogated
the transforming ability of Evi1. By EVI1-mediated serial replating
of murine haematopoietic progenitor cells we show that the
phosphomimetic S196D mutant retained EVI1 function, and
conferred serial replating as we also demonstrated for wt-EVI1
and EVI1-S196A. However, replating with Evi1-S196D was
associated with higher transgene expression compared to wt-EVI1
or EVI1-S196A. Since only a narrow range of EVI1 expression
appears compatible with transformation and replating [12,32] the
significantly higher levels of S196D expression is consistent with
impaired efficacy of the EVI1-S196D that we demonstrate in vitro
and in Rat1 fibroblasts, which is compensated for by higher
transcript levels.
In line with the observation that EVI1-mutations disrupting the
first zinc-finger domain abolish the ability of EVI1 to induce
myelodysplastic syndrome in mice [16], these data confirm a
central role for the first-zinc finger domain of EVI1 in
transformation, which is modulated by phosphorylation. EVI1-
S196 phosphorylation appears to modulate EVI1 function by
reducing affinity of the N-terminal zinc finger domain to specific
DNA target sequences, without evidence of significantly affecting
functions of other domains with respect to transcriptional
regulation.
Zinc finger domain phosphorylation has been detected on other
transcriptional regulators [33,34], and phosphorylation mediated
abrogation of DNA binding with effect on transforming ability has
also been described for other leukemia associated transcription
factors, including HOXA9, which intriguingly cooperates with
EVI1 in leukaemogenesis [18,35]. Given that EVI1 phosphory-
lation at S196 was detected in cells derived from AML originally
arising in an FA-patient, our findings might be in particular
relevant in the context of leukaemia associated with FA. However,
methylation patterns associated with EVI1 overexpression overlap
largely between this FA-derived AML cell line and sporadic AML
[8]. It has previously been reported that DNA binding and
transcriptional regulation of EVI1 is also regulated by acetylation
via the P/CAF acetyltransferase, which prevents EVI1 binding to
Figure 3. EVI1 S196 phosphorylation disrupts DNA binding and transcriptional repression. (A) Electro-mobility shift assay (EMSA) with
GST alone or GST-Evi1 (ZF1-7) fusion proteins corresponding to WT or mutant Evi1 mimicking non-phosphorylated (S196A) or phosphorylated serine
196 (S196D) (upper panel). The DNA-protein complex and the free, labelled DNA probe are indicated. Lower panel: GST-fusion proteins separated on
a 12.5% (w/v) SDS-PAGE gel and stained with colloidal coomassie blue. Specificity of protein/DNA interaction was confirmed by incubation with
excess concentration of unlabelled random DNA substrate (data not shown). Graphs show mean (6s.d.,n = 4) luciferase activity relative to an empty
vector control from reporter gene assays using either (B) a PLZF-luc reporter or (C) a Fos reporter co-transfected into HEK 293 cells with wild-type
Evi1, S196 mutants or empty vector control. Luciferase activities were normalised against Renilla activity and calibrated to the empty vector control,
*P,0.01, ns = non-significant (D) Western blotting of wild-type and mutant Evi1 protein levels in the reporter gene assays.
doi:10.1371/journal.pone.0066510.g003
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the promoter region of its target genes and modulates transcrip-
tional activation [9,36]. This implies complex regulation of EVI1
function by a spectrum of post-translational modifications. We
have addressed the functional consequences of S196 phosphory-
lation in biochemical assays, the Rat1 model and murine
haematopoietic progenitor cells, which suggests a modulatory
effect of S196 phosphorylation, which is likely to be further
confounded by tissue specificity and cellular differentiation.
Therapeutically, it will be important to understand how these
post-translational modifications functionally interact and to
identify mediators and dynamics of S196 phosphorylation.
Investigations are underway to identify the cell signalling pathways
controlling these processes.
Materials and Methods
Cell lines
The EVI1 overexpressing FA derived AML cell line SB1690CB
was established from the leukaemia of an FA patient [5,27] and
maintained under culture conditions as described previously
[5,8,27]. Other cell lines were obtained from DSMZ (Deutsche
Sammlung fu¨r Mikroorganismen und Zellkulturen, Braunschweig,
Germany;). The leukemia cell lines MUTZ-3 and K562 were
maintained as described previously [5,27]. Rat1 cells were
cultured as described before [13,26,37,38]. GP-E86 cells lines
were cultured in DMEM with 5% newborn calf serum, L-
glutamine and penicillin/streptomycin. Plat-E and HEK-293T
cells were cultured as previously described [39].
Western Blot and Immunoprecipitation
EVI1 western blot and immunoprecipitation was carried out
using standard protocols. An EVI1 antibody, raised against the N-
terminal EVI1 epitope MKSEDYPHETMAPDI (Eurogentec,
Liege, Belgium), and anti-EVI1 #2265 (Cell Signalling Technol-
ogy, Boston, MA, USA) were used. For mass spectrometric
analysis EVI1 was immunoprecipitated from protein lysates of
large scale cultures of approximately 66108 SB1690CB cells. Evi1
detection in transformed Rat1 fibroblast was carried out with the
anti-mouse Evi1-SP317 antibody (kind gift of Professor A. Perkins,
Rochester, USA) [40].
Mass spectrometry
EVI1 was analyzed using multiple reaction monitoring-initiated
detection and sequencing (MIDAS) [41,42]. MRM transitions
were designed to detect EVI1 peptides (7 – 24 amino acids in
length) with a single serine, threonine or tyrosine phosphorylation
within a Q1 m/z range from 400 to 1300 and in both a double
Figure 4. EVI1 S196 phosphorylation abrogates Rat1 transformation. (A) Representative photomicrographs of Rat1 fibroblast colonies
transduced with wtEVI1 or S196 mutants (S196A and S196D) retroviral expression vectors. (B) Assays were scored after 24 days and colonies
enumerated for number and size (mean6s.d., n = 3, *P, 0.05). (C) Detection of Evi1 protein in transduced Rat1 fibroblasts shown by western blot on
whole cell lysates using the Evi1-SP137 antibody.
doi:10.1371/journal.pone.0066510.g004
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and triple charge state. A Q3 mass of either 216.0 Da or Q1 minus
98 Da was used to identify tyrosine or serine/threonine
phosphorylation, respectively. Following gel separation of immu-
noprecipitated EVI1, the EVI1 containing band was excised, and
digested with trypsin. Peptides were separated by liquid chroma-
tography prior to MIDAS using electrospray mass spectrometry on
a 4000 Q-TRAP mass spectrometer (AB Sciex, Toronto, Canada).
Molecular modelling of the proximal EVI1 zinc finger
domain
The phosphorylated serine is found in the first EVI1 zinc finger
domain. No crystal structure is available for this domain. In order
to assess the impact of phosphorylation or substitution of S196, a
comparative model was generated using the human C2H2 type
zinc finger of protein 484 (Database http://www.genome.jp/
dbget-bin/www_bget?pdb:2EMH; pdb code 2EMH) as a tem-
plate. For this, the sequences of EVI1 and the template structure
were aligned using ClustalW [43] and 25 models built using
Modeller [44]. The model with lowest discrete optimized protein
energy (DOPE) score was selected. Models mimicking the specific
mutations were built using KiNG (http://kinemage.biochem.
duke.edu.) [45]. In each case all low-energy rotamers [46] were
considered and the rotamer with fewest van der Waals overlap
used. For the phosphorylated serine standard bond lengths were
used.
Plasmids
The retroviral Evi1 expression vector p50FL-neo and the
bacterial expression vector pGEX-Evi1-ZF1-7 encoding the first
seven zinc-fingers of Evi1 fused to GST have been described
previously [6,37,38]. Mammalian expression constructs were
generated by cloning Evi1 excised from p50FL-neo (Wild-type,
S196A, and S196D) into a pCMV backbone. Substitution of S196
in pGEX-EVI1-ZF1-7, p50FL-neo and pMIG-FLAG-Evi1 to
alanine (A), or aspartic acid (D) was achieved by site directed
mutagenesis using the QuikChangeH II XL Kit (Agilent, Santa
Clara, USA). The mutagenesis primer oligonucleotides used were
as follows: S196A FW GCCCTTTATCTGTGAGGTCTG
CCATAAAGCCTATACTCAG; S196A RV CTGAGTA-
TAGGCTTTATGGCAGACCTCACAGATAAAGGGC; and
S196D FW GCCCTTTATCTGTGAGGTCTGCCATAAA-
GACTATACTCAG; S196D RV CTGAGTATAGTCTT-
TATGGCAGACCTCACAGATAAAGGGC. Mutations were
confirmed by DNA sequencing. To generate pMIG-FLAG-Evi1
vectors a SalI FLAG-Evi1 fragment was excised from pCMV-
FLAG-Evi1 (WT, S196A and S196D) and inserted into the XhoI
site of pMIG. The reporter plasmids PLZF-luciferase, Fos-
luciferase (a kind gift from Prof. Andrew Sharrocks, Manchester)
and TK-Renilla luciferase have been previously described [25].
Electromobilty shift assay (EMSA)
EMSA was carried out as described previously [6]. In brief,
E.coli BL21 competent cells were transformed with pGEX-Evi1-
ZF1-7 plasmids encoding for WT or S196-mutated GST-Evi1
fusion proteins. Fusion proteins were affinity purified using
glutathione sepharose 4B and incubated with a double stranded
DNA, sequence 59ACCCATGGAGCTTTGAGCCCTGT-
TATCTTGTCAGGGAAGTGTACCATGGA’3, labelled at the
59 end with IRDye. The reaction product was separated on a
native 5% acrylamide gel and scanned on a Li-Cor Odyssey
system (Li-Cor Biosciences, Lincoln NE, USA) to identify protein-
DNA complexes.
Reporter gene assay
Reporter gene assays were carried out in HEK-293T cells. Cells
were plated out in 6-well plates at 3.56105 cells per well and co-
transfected with 1 mg luciferase reporter plasmid, 1 mg effector
plasmids (WT or mutants) and 5 ng TK-renilla luciferase using
lipofectamine 2000 (Life Technologies, Carlsbad, CA,USA). After
48 hours cells were lysed and firefly and Renilla activity were
assayed using the Dual-luciferase reporter assay (Promega,
Madison, WI, USA) measured on a Victor3 plate reader (Perkin
Elmer, Waltham,USA) or Flash’n Glow luminometer (Berthold
Technologies, Bad Wildbad, Germany).
Rat1 fibroblast transforming assay
Rat1 transduction with p50-M-X-neo, p50FL-neo, p50FL-
196D-neo or p50FL-196A-neo retroviral constructs was carried
out using the retroviral packaging cell line GP+E86, as described
previously [13,26,37,38]. In brief, Rat1 cells were seeded into 100-
mm tissue culture plates at 16106 cells/plate and left to adhere.
Medium was replaced with viral supernatant supplemented with
polybrene (4 mg/mL) until Geneticin (G418, 400 mg/mL, Life
Technologies) selection after 48 hours and maintained for 10 days
to generate stable cell lines. Cells were seeded in soft agar and after
25 days quantified for colony number and size and documented
using a standard inversion microscope.
Serial replating of murine haematopoietic progenitors
This was carried out essentially as previously described [47].
Briefly, bone marrow was harvested from the femurs and tibias of
8-10 week old C57/BL6 mice. C-kit+ cell were isolated using an
Automacs pro system (Miltenyi Biotechnology, Bergisch Glad-
bach, Germany), and pre-stimulated overnight in RPMI 1640
supplemented with recombinant murine IL-3 (10 ng/mL), GM-
CSF (10 ng/mL), SCF (20 ng/mL) and IL-6 (10 ng/mL) in 20%
fetal bovine serum, prior to transduction. Viral supernatant was
generated by transfecting Plat-E packaging cells with WT-Evi1 and
Evi1-S196 mutant pMIG-FLAG-Evi1 or control pMIG retroviral
vectors using Fugene HD transfection reagent. C-kit+ cells were
infected by spinoculation (30 minutes at 1250 x g and 32uC) with
8 mg/mL polybrene. Cells were cultured for an additional two
Figure 5. Serial replating of murine hematopoietic progenitor cells transduced with wtEvi1 and Evi1 phosphorylation site mutants.
(A) Western blot analysis of Evi1 expression in PLAT-E cells two days after transfection with retroviral vectors encoding wtEVI1, Evi1-S196A, Evi1-
S196D or empty vector control. (B) Total colony numbers (mean6s.d, n = 5) formed in serial replating assays by c-kit positive cells transduced with
wtEVI1, S196A, S196D or control retroviral expression vectors. (C) Percentage of cell types (blast, macrophage or other) enumerated by
morphological analysis of May-Gru¨nwald Giemsa stained cytospins after the third round of replating. Mean, n = 4. Photomicrographs of May-
Gru¨nwald-Giemsa-stained cytospins after the third round of replating of transduced cells expressing WT or mutant EVI1 as shown. Scale bar indicates
50 mM. (D) Photomicrographs of May-Gru¨nwald-Giemsa-stained cytospins after the third round of replating of transduced cells expressing WT or
mutant EVI1 as shown. Scale bar indicates 50 mM. (E) Relative Evi1 expression in c-kit+ cells after the first round of plating determined by qRT-PCR
analysis. Mean6s.d, n = 4. *P,0.01. (G) Sanger-Sequencing of Evi1 transcripts from c-kit+ cells after the first round of plating. Electropherograms
illustrating DNA-sequence around codon encoding S196. Nucleotide and amino acid sequence (single letter amino acid code) are shown.
doi:10.1371/journal.pone.0066510.g005
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days in pre-stimulation medium prior to FACS selection of GFP+
cells. Mean transduction efficiency for WT-Evi1 was, 11.9% GFP+
cells; Evi1-196A, 13.8%, Evi1-196D, 14.0%; and pMIG control,
35.1%.
For replating 16104 GFP+ cells were plated out in Methocult
M3231 medium (StemCell Technologies, Grenoble, France)
supplemented with recombinant murine IL-3 (10 ng/mL), GM-
CSF (10 ng/mL), SCF (20 ng/mL) and IL-6 (10 ng/mL). After 7
days colony number and type were enumerated. 16104 cells were
then replated and colonies scored for at least three subsequent
rounds of replating. Cytospin preparations and May-Gru¨nwald
Giemsa stainings were carried out using standard methods.
EVI1 – transcript analysis
RNA was extracted from c-kit+ selected cells with an RNeasy
Kit (Qiagen, Valencia, CA, USA). cDNA was generated using
Omniscript reverse transcriptase (Qiagen) with random nonamers
(Sigma, Dorset, UK) and quantitative RT-PCR reactions were
carried out on an Applied Biosystems 7900 (Life Technologies).
Evi1 qRT-PCR reactions consisted of Taqman universal master-
mix (Life Technologies) and Taqman gene expression assay
(Mm00514814_m1, Applied Biosystems). For sequence analysis an
Evi1 PCR fragment was amplified from cDNA using the following
oligonucleotides: FW, TGTGAAAACTGTGCCAAGGT; RV,
ACTTAGATCCAGGGGCTGGT. Sanger sequencing of the
purified PCR product was carried out using the standard
techniques and the oligonucleotide primer AGGTAAGACCAG-
CAGGATGC.
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